Dr. Kremyanskaya is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
10 E 102nd St
New York, NY 10029Phone+1 212-241-6756Fax+1 212-731-5210
Education & Training
Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 2009 - 2012- Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 2006 - 2009
Perelman School of Medicine at the University of PennsylvaniaClass of 2006
Certifications & Licensure
NY State Medical License 2008 - 2026- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial) Start of enrollment: 2013 Jan 01
- Ruxolitinib in Combination With Autotransplant Start of enrollment: 2015 May 01
- A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) Start of enrollment: 2020 Jun 12
- Join now to see all
Publications & Presentations
PubMed
- 50 citationsA randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia.John Mascarenhas, Heidi E Kosiorek, Josef T Prchal, Alessandro Rambaldi, Dmitriy Berenzon
Blood. 2022-05-12 - 48 citationsPolycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617FBrady L. Stein, Stephen T. Oh, Dmitriy Berenzon, Gabriela S. Hobbs, Marina Kremyanskaya
Journal of Clinical Oncology. 2015-08-31 - 2 citationsSafety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis.Aaron T Gerds, Claire Harrison, Jean-Jacques Kiladjian, Ruben Mesa, Alessandro M Vannucchi
Blood Advances. 2024-09-10
Press Mentions
Protagonist Therapeutics Announces Presentation of Updated Results from Phase 2 Study of Rusfertide in Polycythemia Vera, Selected for Oral Presentation at EHA 2021May 12th, 2021- Hepcidin Mimetic Eliminates Need for Phlebotomy in Polycythemia VeraDecember 18th, 2020
- Protagonist Therapeutics to Present Updated Clinical Data for Hepcidin Mimetic PTG-300 in Polycythemia Vera at the American Society for Hematology (ASH) 2020 Annual MeetingNovember 4th, 2020
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
